scholarly journals Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors

2016 ◽  
Vol 27 ◽  
pp. vi3
Author(s):  
B. Savastano ◽  
C.M. Della Corte ◽  
F. Papaccio ◽  
V. Giuseppe ◽  
G. Esposito ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lines ◽  
First Generation ◽  
Kinase Inhibitors ◽  
Nsclc Cell ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutant

scholarly journals Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression

PLoS ONE ◽  
2010 ◽  
Vol 5 (11) ◽  
pp. e14117 ◽  
Author(s):  
Kathryn E. Ware ◽  
Marianne E. Marshall ◽  
Lydia R. Heasley ◽  
Lindsay Marek ◽  
Trista K. Hinz ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lines ◽  
Kinase Inhibitors ◽  
Acquired Resistance ◽  
Nsclc Cell ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors

scholarly journals Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

2011 ◽  
Vol 17 (19) ◽  
pp. 6322-6328 ◽  
Author(s):  
Geoffrey R. Oxnard ◽  
Yelena Y. Janjigian ◽  
Maria E. Arcila ◽  
Camelia S. Sima ◽  
Samantha L. Kass ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutant
Sign in / Sign up

Export Citation Format

Share Document